共查询到20条相似文献，搜索用时 359 毫秒
1.
通过复方泰乐菌素注射液对仔猪气喘病例的治疗来评价复方泰乐菌素注射液对防治猪气喘病的应用效果,为临床使用提供依据。结果表明:复方泰乐菌素注射液治疗猪气喘病的效果明显,推荐剂量按体重0.1mL/kg肌肉注射。 相似文献
2.
[目的]验证长效土霉素注射液对猪喘气病的治疗效果。[方法]用30%长效土霉素注射液(0.1mL/kg)注射治疗猪喘气病,并设恩诺沙星注射液组(0.1mL/kg)、阳性感染组及阴性健康组为对照组,从临床症状、猪肺病变程度以及平均增重来进行对比试验。[结果]30%长效土霉素注射液组和恩诺沙星注射液组对猪喘气病均有效,同阳性对照组比较差异显著,且30%长效土霉素注射液组治疗效果优于恩诺沙星注射液组。[结论]综合增重、肺病变程度等指标,认为长效土霉素注射液组对猪喘气病较适合,并有较好的治疗效果。推荐剂量:每千克体重0.1mL,只注射1次即可,病情严重者3d后再注射1针。 相似文献
3.
为了验证喘毒劲敌注射液对猪气喘病的疗效 ,选择体重约 60kg ,经诊断患气喘病的三元杂种猪 1 80头 ,随机分为 5个组进行治疗试验 ,结果表明 ,高、中、低剂量喘毒劲敌注射液对猪气喘病治疗总有效率为 80 %左右 ,与不给药对照组相比 ,差异极显著 ( p <0 0 1 ) ,与对照药物复方蟾酥注射液相比 ,差异不显著 ( p >0 0 5 )。喘毒劲敌注射液对猪气喘病疗效确实 ,可在临床上推广应用。 相似文献
4.
试验旨在观察长沙拜特KK之友(30%替米考星注射液)对猪喘气病、猪传染性胸膜肺炎、猪肺疫、副猪嗜血杆菌、猪乳房炎的防治效果及安全用量。本试验均按替米考星6mg/kg体重肌肉注射第一针,注射24h后,康复慢的病猪按替米考星5mg/kg体重重复注射一次。试验结果表明第一针后病猪病情得到明显控制或缓解,第二针后基本恢复正常,且注射后无明显药物应激反应。30%替米考星注射液按6mg/kg肌肉注射对治疗猪气喘病、猪传染性胸膜肺炎、猪肺疫、猪嗜血杆菌病、猪乳房炎均作用显著且用量安全,值得在各种规模化猪场推广使用。 相似文献
5.
三组猪分别按2.5 mg/kg的剂量肌肉注射拜有利5%、恩诺沙星注射液A、恩诺沙星注射液B三种药物,HPLC法测定血药浓度,Winnonlin6.1软件拟合血药浓度—时间数据,计算参数。三种注射液均符合一室开放模型,峰浓度分别为:0.87、0.63、0.49μg/mL,AUC分别为6.32、5.31、3.45 h.μg.mL-1。实验结果表明,拜有利5%在猪体内的药代动力学参数优于注射液B,注射液B的优于注射液A,提示恩诺沙星注射液B与拜有利5%相比临床防治效果略差,药物吸收可做进一步改进。 相似文献
6.
《中国兽医学报》2016,(11):1908-1915
为了研究复方氟苯尼考注射液的体外抗菌活性及对人工感染巴氏杆菌仔猪的保护效果。本研究采用体外抑菌试验采用试管二倍稀释法,测定复方氟苯尼考注射液和单方氟苯尼考注射液对多杀性巴氏杆菌、副猪嗜血杆菌、猪传染性胸膜肺炎放线杆菌及链球菌的最小抑菌浓度(MIC)。体内治疗试验是将复方氟苯尼考注射液分为20、40、60mg/kg 3个剂量组与氟苯尼考对照组(40mg/kg)以及氟尼辛葡甲胺对照组(3.65mg/kg)以颈部肌肉注射治疗人工感染多杀性巴氏杆菌的仔猪。体外抑菌试验结果显示,复方氟苯尼考注射液对多杀性巴氏杆菌、副猪嗜血杆菌、猪传染性胸膜肺炎放线杆菌及链球菌的MIC分别为0.59、1.09、0.59、2.12mg/L;氟苯尼考注射液对多杀性巴氏杆菌、副猪嗜血杆菌、猪传染性胸膜肺炎放线杆菌及链球菌的MIC分别为1.12、6.13、17.86、17.86mg/L。保护性试验结果显示,复方氟苯尼考注射液低、中、高剂量组增重率分别为(10.19±4.84)、(14.33±4.07)、(15.53±5.38)kg,死亡率分别为10%、10%、0,好转率分别为60%、90%、100%,治愈率分别为20%、90%、100%;氟苯尼考组的增重率为(9.90±4.25)kg;氟尼辛葡甲胺组的增重率为(8.02±3.83)kg。结果表明,复方氟苯尼考注射液对多杀性巴氏杆菌、副猪嗜血杆菌、猪传染性胸膜肺炎放线杆菌及链球菌的抑菌效果强于单方氟苯尼考注射液;复方氟苯尼考注射液对人工感染多杀性巴氏杆菌仔猪的保护作用也优于氟苯尼考注射液。建议本品的治疗剂量为颈部肌肉注射40mg/kg,每7d给药1次,连用2次,如症状严重可2d给药1次,连用2次。 相似文献
7.
为了比较3种常用复合麻醉剂对小型猪循环、呼吸影响,将中国实验用小型猪分成3组进行比较.第1组肌肉注射小型猪复合麻醉剂(XFM)0.15 mL/kg体重;第2组联合肌肉注射氯胺酮8 mg/kg体重、安定1 mg/kg体重;第3组联合肌肉注射速眠新Ⅱ0.1 mL/kg体重、戊巴比妥钠10.5 mg/kg体重.试验结果表明,氯胺酮和速眠新Ⅱ对小型猪麻醉后的循环、呼吸系统有一定的抑制作用,尤其使用速眠新Ⅱ进行麻醉的小型猪血氧饱和度(SpO2)下降明显.XFM麻醉后小型猪循环、呼吸系统无明显影响,SpO2、血压(BP)以及呼吸系统各指标均在生理正常范围内,比较之下更适合用于小型猪的麻醉. 相似文献
8.
《中国兽医杂志》2014,(10)
为探讨蟾酥注射液对仔猪致病性大肠杆菌感染的保护作用及其与免疫功能的关系,按体重给仔猪肌肉注射高(0.2 m L/kg),中(0.1 m L/kg),低(0.05 m L/kg)三种剂量的蟾酥注射液,每天1次,连用3 d;用穿心莲注射液(0.2 m L/kg)作为药物对照组。第4天用致病性大肠杆菌进行攻毒(肌肉注射3×109CFU/m L×4.0 m L),观察仔猪腹泻情况及测定外周血T淋巴细胞亚群的变化。结果显示,高、中剂量蟾酥注射液对人工感染猪致病性大肠杆菌具有保护作用,与穿心莲注射液对照组相似,但低剂量组效果稍差。不同剂量的蟾酥注射液在用药后对T淋巴细胞阳性率及猪CD4+细胞增殖均有显著的促进作用。结论:蟾酥注射液能增强猪的非特异性免疫功能,尤其是细胞免疫功能,对猪致病性大肠杆菌感染具有保护作用。 相似文献
9.
增效联磺注射液药代动力学和体外抗菌活性的研究及对仔猪白痢的疗效试验 总被引：2，自引：0，他引：2
选用6头健康杂种猪,肌肉注射增效联磺注射液(0.3 mL/kg体重)进行药代动力学研究.高效液相色谱法测定该制剂中SMM、SMZ和TMP的血药浓度,用MCPKP计算机程序处理所得血药浓度-时间数据.肌肉注射增效联磺注射液后SMM、SMZ和TMP的药-时数据适合一级吸收二室模型,主要药代动力学参数:T1/2Ka分别为(0.285±0.087)、(0.756±0.366)和(0.402±0.131), T1/2α分别为(4.11±1.35)、(2.09±0.85) 和(3.18±1.20)h,T1/2β分别为(30.92±12.84)、(8.32±3.34) 和(20.03±7.74) h,Cmax分别为(15.32±3.06)、(29.33±2.68) 和(4.03±0.65) μg·mL-1,AUC 分别为(0.371±0.129) 、(0.193±0.022)和(0.417±0.086) mg·L-1·h-1.用大肠杆菌C83902、巴氏杆菌C48-1对增效联磺注射液进行体外抗菌活性测定,结果MIC均＜1.22 μg/mL(以SMM计).对猪肌肉注射增效联磺注射液,其有效浓度可保持48 h,临床上以0.3 mL/kg体重剂量治疗仔猪白痢可48 h肌肉注射1次;增效联磺注射液与复方磺胺间甲氧嘧啶注射液及复方磺胺甲噁唑注射液对仔猪白痢的疗效相当,但使用次数减少. 相似文献
10.
11.
Barbosa BF Gomes AO Ferro EA Napolitano DR Mineo JR Silva NM 《Veterinary parasitology》2012,187(1-2):44-52
Currently, toxoplasmosis is treated with sulfadiazine and pyrimethamine. However, this treatment presents several adverse side effects; thus, there is a critical need for the development and evaluation of new drugs, which do not present the same problems of the standard therapy. Enrofloxacin is a fluoroquinolone antibiotic known to control infection against several bacteria in veterinary medicine. Recently, this drug has demonstrated protective effects against protozoan parasites such as Neospora caninum. The present study aimed to determine the effect of enrofloxacin in the control of Toxoplasma gondii infection. For this purpose, human foreskin fibroblast (HFF) cells were infected with T. gondii RH strain and treated with sulfadiazine, penicillin/streptomycin, pyrimethamine, or enrofloxacin. Following treatment, we analyzed the infection index, parasite intracellular proliferation and the number of plaques. Additionally, tissue parasitism and histological changes were investigated in the brain of Calomys callosus that were infected with T. gondii (ME49 strain) and treated with either sulfadiazine or enrofloxacin. Enrofloxacin was able to reduce the infection index, intracellular proliferation and the number of plaques in HFF cells infected by T. gondii in comparison with untreated or penicillin/streptomycin-treated ones. Enrofloxacin was more protective against T. gondii in HFF infected cells than sulfadiazine treatment (P<0.001). In addition, pyrimethamine, enrofloxacin or the associations of sulfadiazine plus pyrimethamine, enrofloxacin plus sulfadiazine or enrofloxacin plus pyrimethamine-treatments were able to reduce the plaque numbers in HFF cells infected by T. gondii when compared to medium, penicillin/streptomycin or sulfadiazine alone. In vivo experiments demonstrated that enrofloxacin diminished significantly the tissue parasitism as well as the inflammatory alterations in the brain of C. callosus infected with T. gondii when compared with untreated animals. Based on our findings, it can be concluded that enrofloxacin is a potential alternative drug for the treatment of toxoplasmosis. 相似文献
12.
2020年2月份山西某大型规模猪场育肥猪突发呼吸困难,无过多症状表现,即突然死亡,发病率为2%,死亡率1.5%左右。实验室以病死猪为研究对象,综合死亡猪只脏器病变状况观察,无菌采集病死猪的肺脏、肝脏、脾脏病料,进行RT-PCR检测猪蓝耳病原;用含1%NAD和5%胎牛血清的TSA琼脂培养基进行细菌分离培养和纯化,经形态学鉴定、PCR鉴定、16Sr RNA基因序列进化树构建等方法,结果显示:该发病猪群为猪繁殖与呼吸障碍综合征并发猪胸膜肺炎放线杆菌感染。药敏试验结果显示:该猪胸膜肺炎放线杆菌对安普霉素、硫酸黏菌素、替米考星+氟苯尼考、替米考星+阿莫西林、氟苯尼考、头孢噻呋钠+硫酸黏菌素、头孢喹肟、头孢噻呋钠+新霉素、替米考星+头孢噻呋钠、多西环素+氟苯尼考、头孢噻呋钠+阿莫西林、阿莫西林+克拉维酸钾、头孢噻呋钠+恩诺沙星、新霉素、头孢噻呋钠、安普霉素+头孢噻呋钠敏感。对恩诺沙星耐药。本实验室根据临床及检测结果制定治疗方案,为该猪场的猪繁殖与呼吸障碍综合征并发猪胸膜肺炎的临床诊断及用药提供了理论依据。 相似文献
13.
14.
15.
混合感染背景下的猪气喘病较难控制,介绍了猪气喘病的发病特点,常用药物的敏感度评价、疫苗效果评价和猪场猪气喘病的检查检测方法,结合作者实际经验强调了饲养管理要点,指出了种猪场净化猪气喘病的方法步骤,为混合感染下控制猪气喘病提供参考。 相似文献
16.
Colahan PT Bailey JE Johnson M Rice BL Chou CC Cheeks JP Jones GL Yang M 《Veterinary therapeutics : research in applied veterinary medicine》2002,3(1):49-63
Following the regimen used to treat equine protozoal myeloencephalitis, sulfadiazine (20 mg/kg) and pyrimethamine (1mg/kg) were administered orally once daily to 12 physically conditioned Thoroughbred horses for 4 consecutive days. The horses were randomly assigned to two test groups in a crossover design, with each horse serving as its own control. A stepwise exercise stress test was conducted to exhaustion. No effect on athletic performance was observed, and only marginal effects were noted in some hematologic and serochemical measurements, including decreased total white blood cell counts, red blood cell distribution width, total hemoglobin, serum sodium, and serum chloride. Serum folic acid concentration decreased significantly following sulfadiazine/pyrimethamine treatment. 相似文献
17.
C R Clarke C R Short R E Corstvet D Nobles 《American journal of veterinary research》1989,50(9):1551-1556
A study was designed to determine the effect of Pasteurella haemolytica infection on the rate and extent of penetration of sulfadiazine and trimethoprim into tissue chambers implanted SC in cattle. Thermoplastic tissue chambers were implanted SC in 6 calves. At 35 days after implantation, sulfadiazine (25 mg/kg of body weight) and trimethoprim (5 mg/kg) were administered IV to 5 of the calves. Chamber fluid and blood samples were collected from each animal at various time intervals for 24 hours after administration. Ten days later, all chambers were inoculated with P haemolytica serotype 1. At 36 hours after inoculation, a second pharmacokinetic study was conducted, using sulfadiazine and trimethoprim. Drug doses and sampling schedules were identical to those used prior to inoculation. A histologic study of infected chamber tissue was conducted, using the calf not included in the pharmacokinetic studies. Disposition curves of antimicrobials in serum and chamber fluid were well described by 2-compartment and 1-compartment pharmacokinetic models, respectively. Inoculation of P haemolytica into tissue chambers was accompanied by marked changes in the composition of chamber fluid. Increased total protein and albumin concentrations, decreased pH, and disruption of chamber tissue vasculature were associated with a significant increase in the penetration of sulfadiazine and trimethoprim into infected tissue chambers, compared with that in noninfected chambers. This increased penetration was accompanied by increases in the apparent volume of distribution for sulfadiazine and trimethoprim. 相似文献
18.
Tomoyuki Shimazu Liushiqi Borjigin Yuki Katayama Meihua Li Takumi Satoh Kouichi Watanabe Haruki Kitazawa Sang‐gun Roh Hisashi Aso Katoh Kazuo Yoshihito Suda Akiko Sakuma Mituru Nakajo Keiichi Suzuki 《Animal Science Journal》2014,85(4):365-373
We recently developed a Landrace line that is resistant to mycoplasmal pneumonia of swine (MPS) infection by genetic selection for five generations, and we reported that the immunophenotype of this line is different from that of the non‐selected line in terms of changes in peripheral blood leukocyte population after MPS vaccination. This study followed up previous findings demonstrating changes in soluble factors in blood, namely, hormones, Mycoplasma hyopneumoniae‐specific immunoglobulin G (IgG), and cytokines. These two lines were injected with MPS vaccine on days ?7 and 0 after blood sampling on those days, and blood samples were collected on days ?14, ?7, 0, 2, 7 and 14. We found changes in the levels of many hormones and cytokines in both lines. However, we found that only growth hormone (GH) and interferon (IFN)‐γ levels were statistically different between these two lines. GH concentration was reduced (day 0) and IFN‐γ concentration was increased (day 14) in the MPS‐selected line compared with the non‐selected line, despite unchanged IFN‐γ messenger RNA expression in blood cells. Although detailed mechanisms underlying these phenotypes remain unsolved, these traits would be useful to improve MPS resistance in pig production and provide an insight into MPS infection. 相似文献
19.
宁夏地区牛支原体药物敏感性分析 《畜牧与饲料科学》2022,43(3):112-116
[目的]提高牛支原体病治疗效果。[方法]应用微量肉汤稀释法对宁夏地区分离鉴定的74株牛支原体进行药物敏感性分析。[结果]恩诺沙星的MIC分布范围最小,MIC50与MIC90最小,其次是大观霉素、庆大霉素和卡那霉素;试验菌株对大观霉素的耐药率最低（12%）,其次为恩诺沙星（22%）,对庆大霉素和卡那霉素的耐药率最高且相同（36%）;肺分离株耐药性最强,关节液分离株次之,乳汁分离株最弱。[结论]恩诺沙星对牛支原体的体外抑菌效果最好,但易产生耐药性,应注意用药剂量和时长;肺分离株耐药性最强可能与呼吸道感染牛支原体的概率大且频繁使用抗生素有关。 相似文献
20.
Murphy DJ Todhunter RJ Fubini SL Vernier-Singer M Straubinger RK Lust G 《Veterinary surgery : VS》2000,29(6):546-557
OBJECTIVE: To study in vitro (1) the dose-response relationships between proteoglycan metabolism in normal and corticosteroid-treated articular cartilage; (2) long-term proteoglycan metabolism after treatment of articular cartilage with corticosteroids; and (3) the effect of corticosteroids on proteoglycan metabolism in articular cartilage treated with monocyte-conditioned medium (MCM). STUDY DESIGN: Equine and canine articular cartilage explants were treated with corticosteroids and MCM. Proteoglycan synthesis and degradation were measured by radioactive labeling in short-term culture, and the long-term effect of corticosteroid treatment on proteoglycan metabolism was studied in normal explants. ANIMALS: Two young cross-breed horses and 3 young Labrador retrievers. METHODS: Equine articular cartilage explants were incubated in medium containing methylprednisolone sodium succinate (MPS) at 0, .001, .01, .1, 1, and 10 mg/mL (final concentration) for 1 day and then in fresh medium without MPS. Proteoglycan synthesis was measured by incorporation of sodium [35S]sulfate at 1, 3, 7, 10, and 13 days after initial treatment with MPS. Proteoglycan release was measured from separate explants prelabeled with sodium [35S]sulfate and treated similarly. Equine articular cartilage explants were treated with equine MCM simultaneously with, and 24 hours before MPS, at 0, 0.01, 0.1, 1, or 5 mg/mL for 72 hours. Proteoglycan synthesis and degradation in these explants was compared. Proteoglycan synthesis and degradation were measured similarly in canine articular cartilage explants treated simultaneously with canine MCM and MPS at 0, 0.001, 0.01, 0.1, 1 and 10 mg/mL for 72 hours. Equine articular cartilage explants treated with 0, 0.01, 0.1, 1, and 5 mg/mL of MPS for 72 hours were evaluated histologically. RESULTS: Proteoglycan synthesis in normal equine articular cartilage was severely depressed by 10 mg/mL MPS for 24 hours, and proteoglycan synthesis failed to recover after 13 days of culture in medium without MPS. Cartilage treated with 5 mg/mL MPS had pyknotic chondrocyte nuclei and empty lacunae. Concentrations of 1 and 0.1 mg/mL MPS depressed proteoglycan synthesis in normal equine cartilage explants. For these 2 concentrations, proteoglycan synthesis recovered 2 days after MPS removal and increased significantly (P < .05) 7 days after treatment with MPS compared with controls without MPS. Concentrations of 0.001 and 0.01 mg/mL MPS did not significantly affect proteoglycan synthesis in normal equine cartilage explants. Cumulative proteoglycan loss over 13 days in culture from normal equine explants treated for 24 hours with different concentrations of MPS was not significantly different between treatment groups at any time point. MCM significantly depressed proteoglycan synthesis in both canine and equine articular cartilage explants and significantly increased proteoglycan release. These effects were prevented in the canine explants by simultaneous treatment with MPS at 1 and 0.1 mg/mL, and proteoglycan release induced by MCM in equine articular cartilage was inhibited by 1 mg/mL MPS. CONCLUSIONS: Concentrations of 1.0 and 0.1 mg/mL MPS alleviated articular cartilage degradation in MCM-treated articular cartilage in vitro. These concentrations of MPS in contact with normal cartilage explants for 24 hours are unlikely to be detrimental in the long term to proteoglycan synthesis. The response of articular cartilage to MPS was affected by treatment with MCM so that results of experiments with normal articular cartilage explants may not reflect results obtained with abnormal cartilage. CLINICAL RELEVANCE: It may be possible to find an intraarticular concentration of corticosteroid that protects articular cartilage against cytokine-induced matrix degradation yet not have prolonged or permanent detrimental effects on chondrocyte matrix synthesis. 相似文献